Literature DB >> 1978026

Clearance of Rh D-positive red cells with monoclonal anti-D.

A Thomson1, M Contreras, B Gorick, B Kumpel, G E Chapman, R S Lane, P Teesdale, N C Hughes-Jones, P L Mollison.   

Abstract

Two human monoclonal antibodies, one IgG3 and one IgG1, with anti-Rh D specificity, were tested for their ability to clear red cells. Samples of red cells from 12 D-positive subjects were sensitised in vitro with various amounts of antibody, the number of antibody molecules bound to the cells was estimated, and the cells were reinjected into the donor's circulation. Both antibodies mediated clearance but substantially fewer IgG3 than IgG1 antibody molecules were required to produce a given rate of clearance. The IgG3 antibody was slightly more effective than polyclonal anti-D, as judged by comparison with previously published results. Since there is believed to be an association between the rate of red cell clearance by anti-D and the ability of the antibody to suppress D immunisation, the IgG3 monoclonal antibody may prove suitable for the immunoprophylaxis of Rh D haemolytic disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1978026     DOI: 10.1016/0140-6736(90)92767-c

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  10 in total

1.  The clearance kinetics of autologous RhD-positive erythrocytes coated ex vivo with novel recombinant and monoclonal anti-D antibodies.

Authors:  G E Chapman; J R Ballinger; M J Norton; D R Parry-Jones; N A Beharry; C Cousins; C H Dash; A M Peters
Journal:  Clin Exp Immunol       Date:  2007-08-03       Impact factor: 4.330

2.  Deaths from Rh haemolytic disease in England and Wales in 1988 and 1989.

Authors:  R M Hussey; C A Clarke
Journal:  BMJ       Date:  1991-08-24

Review 3.  The role of antenatal immunoprophylaxis in the prevention of maternal-foetal anti-Rh(D) alloimmunisation.

Authors:  Giancarlo Maria Liumbruno; Angelo D'Alessandro; Federica Rea; Vanessa Piccinini; Liviana Catalano; Gabriele Calizzani; Simonetta Pupella; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2010-01       Impact factor: 3.443

4.  Antibody responses to the blood group antigen D in SCID mice reconstituted with human blood mononuclear cells.

Authors:  K A Leader; L M Macht; F Steers; B M Kumpel; C J Elson
Journal:  Immunology       Date:  1992-06       Impact factor: 7.397

5.  The functional activity of Fc gamma RII and Fc gamma RIII on subsets of human lymphocytes.

Authors:  A G Hadley; B Zupanska; B M Kumpel; K A Leader
Journal:  Immunology       Date:  1992-07       Impact factor: 7.397

Review 6.  Lessons learnt from many years of experience using anti-D in humans for prevention of RhD immunization and haemolytic disease of the fetus and newborn.

Authors:  B M Kumpel
Journal:  Clin Exp Immunol       Date:  2008-08-22       Impact factor: 4.330

7.  Clearance of red cells by monoclonal IgG3 anti-D in vivo is affected by the VF polymorphism of Fcgamma RIIIa (CD16).

Authors:  B M Kumpel; M De Haas; H R Koene; J G J Van De Winkel; M J Goodrick
Journal:  Clin Exp Immunol       Date:  2003-04       Impact factor: 4.330

Review 8.  The prevention and management of haemolytic disease of the newborn.

Authors:  M Contreras; M de Silva
Journal:  J R Soc Med       Date:  1994-05       Impact factor: 18.000

9.  Anti-D monoclonal antibodies from 23 human and rodent cell lines display diverse IgG Fc-glycosylation profiles that determine their clinical efficacy.

Authors:  Belinda M Kumpel; Radka Saldova; Carolien A M Koeleman; Jodie L Abrahams; Agnes Hipgrave Ederveen; Kathryn L Armour; Natalia I Olovnikova; Gestur Vidarsson; Rick Kapur; Pauline M Rudd; Manfred Wuhrer
Journal:  Sci Rep       Date:  2020-01-30       Impact factor: 4.379

10.  Clearance of human IgG1-sensitised red blood cells in vivo in humans relates to the in vitro properties of antibodies from alternative cell lines.

Authors:  Kathryn L Armour; Cheryl S Smith; Natasha C Y Ip; Cara J Ellison; Christopher M Kirton; Anthony M Wilkes; Lorna M Williamson; Michael R Clark
Journal:  PLoS One       Date:  2014-10-10       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.